The high specificity of the heterodimeric EGFRxHER2 T-BsAb for EGFR+HER2+ double-positive PDAC tumors could offer a strategy to spare healthy single-positive tissues and reduce on-target/off-tumor side effects. Here, EGFR is linked to neoplasm.